Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01215
|
|||||
| Drug Name |
Chlorcyclizine
|
|||||
| Synonyms |
1-(4-Chlorobenzhydryl)-4-methylpiperazine; Alergicide; Chlorcycline; Chlorcyclizine [INN:BAN]; Chlorcyclizinum; Chlorcyclizinum [INN-Latin]; Chlorocycline; Chlorocyclizine; Clorciclizina; Clorciclizina [DCIT]; Clorciclizinio [INN-Spanish]; Compound 47-282; Di-Paralene; Di-paralen; Diparalene; HSDB 3217; Histachlorazene; Histantin; Histantine; N-Methyl-N'-(4-chlorobenzhydryl)piperazine; NSC 25246; Perazyl; Piparalene; Trihistan; chlorcyclizine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Phase 1 | [1] | |||
| Therapeutic Class |
Antihistamines
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H21ClN2
|
|||||
| Canonical SMILES |
CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
|
|||||
| InChI |
InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3
|
|||||
| InChIKey |
WFNAKBGANONZEQ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 82-93-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 300.8 | Topological Polar Surface Area | 6.5 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
4.5
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:94402
|
|||||
| DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT02118012) Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C | |||||
| 2 | Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.